Phase 1 study
Testing the safety, tolerability, and efficacy of NNZ-2591
NNZ-2591 is an investigational oral medicine which aims to improve the impaired connections and signaling between brain cells.
Below is a list of inclusion criteria.
See the full list of eligibility criteria on the clinical trials website.
- Have a diagnosis of Angelman syndrome
- Between 3-17 years old
- Be able to swallow a liquid medication
- Participate for approximately 19 weeks with a combination of in-clinic, remote and telehealth consultations.
Locations & Contacts
Children’s Health Queensland Hospital and Health Service
Honey Heussler CHQ_CCTRND@health.qld.gov.au | (07) 30697532
Prof Ingrid Scheffer firstname.lastname@example.org | (03) 9035 7361
Sydney Children’s Hospital, Randwick
Dr Alexandra Johnson SCHN-SCHNeurologyresearch@health.nsw.gov.au | (02) 93821549